Isabelle Demeestere, MD, PhD, Université Libre de Bruxelles (ULB), Brussels, Belgium, emphasizes the importance of addressing gonadotoxicity in standard chemotherapy for younger patients with cancer. Preserving future fertility is crucial for quality of life, and emerging strategies aim to reduce chemotherapy doses and toxicity by personalizing treatment based on patient response. These tailored approaches have demonstrated significant benefits, including improved recovery of ovarian and sperm function, offering hope for reproductive health in cancer survivors. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть